HUMAN PAPILLOMAVIRUS (HPV) AND CYTOMEGALOVIRUS (CMV) THERAPEUTICS MARKET ANALYSIS

Human Papillomavirus (HPV) And Cytomegalovirus (CMV) Therapeutics Market, by Drug Type (HPV Therapeutics (Immunomodulatory Agents, Keratolytic Agents, Anti-Neoplastic Agents, and Sinecatechins) and CMV Therapeutics (Ganciclovir/Valaganciclovir, Foscarnet, and Cidifovir), by Application (HPV Therapeutics- Genital warts, Cervical cancer, Epidermodysplasia Verrucifdormis, and Others) and (CMV Therapeutics-CMV Retinitis, Pneumonia, Gastrointestinal Ulcers, Encephalitis, and Others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

Published In : Jun 2019
Code : CMI2707
Pages :167
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Global Human Papillomavirus (HPV) and Cytomegalovirus (CMV) Therapeutics Market- Regional Analysis

Regional segmentation of the global human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market is expected to account for the largest market share, owing to increasing initiatives for treatment of cervical cancer by health regulatory authorities in this region. For instance, in November 2018, the Pan American Health Organization (PAHO) launched its Communication Campaign with the slogan, ‘Don’t let cervical cancer stop you’. The aim of the campaign was to create awareness among the people for prevention of cervical cancer (caused by HPV infection).

Furthermore, Asia Pacific is projected to witness significant growth in the global human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market during the forecast period, owing to increasing partnership of hospitals for the treatment of cervical cancer. For instance, in May 2019, Parirenyatwa Hospital (Zimbabwe’s largest referral hospitalannounced its partnership with China's Hunan Provincial Maternal Hospital. Under this partnership, both hospitals offer free cervical cancer screening and treatment to women in Zimbabwe.

Europe is also expected to gain significant share in the global human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market over the forecast period, attributed to increasing products upgrade by key players. For instance, in March 2015, Fujirebio Europe upgraded its HPV genotyping panel with the launch of its new INNO-LiPA HPV Genotyping Extra II assay. It is used for HPV type specific patient monitoring and cervical cancer treatment.